RxDoctor Payments Data

Jahnavi Sawhney, MD

Gastroenterology · New York, NYNPI 1053598227

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 39.5% of the total. That places this record below the midpoint for gastroenterology clinicians in NY, where the typical reported total is $1,827.

$366in general payments, 2019–2025

Across 14 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$144
  • Madrigal Pharmaceuticals$115
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$68
  • Gilead$15
  • Ironwood Pharmaceuticals, Inc$12
  • Merck$11
$151,548in research payments, 2019–2025

Across 53 payments — averaging $2859.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$120K
  • Gilead$24K
  • Intercept Pharma Europe Ltd.$8K
  • Merck$194

What the payments were for

  • Food & beverage$366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$366 in reported general payments places this provider in the 25th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024
$24,504
Medicare patients
59
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide18$14,566
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates16$952
Pantoprazole Sodium43$185
Omeprazole15$80
Ondansetron Hcl21$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$144$14,56618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →